NeurAxis, Inc. Hits New 52-Week High of $6.30, Up 115.75%

NeurAxis, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 6.30 on March 2, 2026. This achievement marks a remarkable increase of 115.75% over the past year, significantly outperforming the S&P 500, which has seen a gain of 17.36% during the same period. With a market capitalization of USD 59 million, NeurAxis operates in a competitive industry characterized by rapid innovation and development. The company's financial metrics reflect its current standing, with a price-to-book ratio of 25.78. However, it is important to note that NeurAxis is currently loss-making, as indicated by its negative P/E ratio and a return on equity of -330.30%. Additionally, the company has a debt-to-equity ratio of -1.80, suggesting a unique financial structure. The stock's previous 52-week low was recorded at USD 1.33, highlighting the significant upward movement in its price. This milestone underscores NeurAxis's evolving position within the market and its potential for continued development in the biotechnology landscape.